COLLAGE

What this means for you

Approved and waiting on proof of use. It will register unless the applicant drops it, and its 28 Oct 2024 filing date already counts against anyone who files later.

Record

Serial number

98824432

Mark type

Stylized text

Filed

28 Oct 2024

Published for opposition

02 Dec 2025

Attorney of record

Christina M. Licursi

Goods and services

• Class 005 — Pharmaceuticals: Pharmaceutical preparations for the treatment of genetic and genomic diseases and disorders, neurological diseases and disorders, muscular diseases and disorders, neuromuscular diseases and disorders, cardiovascular diseases and disorders, metabolic diseases and disorders, cardiometabolic diseases and disorders, endocrine diseases and disorders, and kidney diseases and disorders; pharmaceutical preparations, namely, RNA medicines, oligonucleotide therapeutics, and polynucleotide therapeutics; biopharmaceutical preparations and agents, namely, pharmaceutical preparations for the treatment of genetic and genomic diseases and disorders, neurological diseases and disorders, muscular diseases and disorders, neuromuscular diseases and disorders, cardiovascular diseases and disorders, metabolic diseases and disorders, cardiometabolic diseases and disorders, endocrine diseases and disorders, and kidney diseases and disorders, and RNA medicines, oligonucleotide therapeutics, and polynucleotide therapeutics
• Class 042 — Scientific and technological services: Pharmaceutical research and development; scientific research and development; medical research and development in the field of medical preparations; pharmaceutical research and analysis services using machine learning analytics for drug efficacy and safety; technical consultation services and product development for others in the fields of biotechnology and pharmaceuticals; pharmaceutical and scientific research and development relating to RNA targeting and assay development; platform as a service (PaaS) featuring computer software platforms for performing drug discovery and development and biotechnology research; pharmaceutical drug development services related to proteins, ribosomes, RNA, and DNA

Owner

• Collage Bio Inc., Menlo Park, CA, US
• Collage Bio Inc., Menlo Park, CA, US

Prosecution history

• 27 Jan 2026 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
• 02 Dec 2025 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
• 02 Dec 2025 — PUBLISHED FOR OPPOSITION
• 26 Nov 2025 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
• 04 Nov 2025 — APPROVED FOR PUB - PRINCIPAL REGISTER
• 03 Nov 2025 — TEAS/EMAIL CORRESPONDENCE ENTERED
• 03 Nov 2025 — CORRESPONDENCE RECEIVED IN LAW OFFICE
• 03 Nov 2025 — TEAS RESPONSE TO OFFICE ACTION RECEIVED
• 07 Aug 2025 — APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
• 07 Aug 2025 — APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
• 08 May 2025 — NOTIFICATION OF NON-FINAL ACTION E-MAILED
• 08 May 2025 — NON-FINAL ACTION E-MAILED
• 08 May 2025 — NON-FINAL ACTION WRITTEN
• 29 Apr 2025 — ASSIGNED TO EXAMINER
• 27 Apr 2025 — NEW APPLICATION OFFICE SUPPLIED DATA ENTERED